Application of the yeast-surface-display system for orally administered salmon calcitonin and safety assessment

Biotechnology Progress

Volumn 26, Issue 4, 2010, Pages 968-974

  Sun, Ping Nan ^a   Zhang, Xue Cheng ^b   Chen, Yun Song ^b   Zang, Xiao Nan ^b  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

Saccharomyces cerevisiae; Safety assessment; Salmon calcitonin; Yeast surface display system

Indexed keywords

ADVERSE EFFECT; BODY WEIGHT; CELL SURFACES; CLINICAL APPLICATION; DISPLAY SYSTEM; DNA FRAGMENT; HEMATOLOGICAL PARAMETERS; IN-VITRO; IN-VITRO BIOACTIVITY; IN-VIVO; INDIRECT IMMUNOFLUORESCENCE; MANUFACTURING COST; ORAL ADMINISTRATION; ORAL DELIVERY; S.CEREVISIAE; SACCHAROMYCES CEREVISIAE; SAFETY ASSESSMENTS; SALMON CALCITONIN; SERUM CHEMISTRY; WISTAR RAT;

CELL MEMBRANES; CLONING; DISPLAY DEVICES; FLOW CYTOMETRY; RATS;

YEAST;

CALCITONIN; SALCATONIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BODY WEIGHT; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HAMSTER; MALE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ORAL DRUG ADMINISTRATION; RAT; SACCHAROMYCES CEREVISIAE; WISTAR RAT;

ADMINISTRATION, ORAL; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BODY WEIGHT; CALCITONIN; CRICETINAE; FLUORESCENT ANTIBODY TECHNIQUE; MALE; MOLECULAR SEQUENCE DATA; RATS; RATS, WISTAR; SACCHAROMYCES CEREVISIAE;

RATTUS NORVEGICUS; SACCHAROMYCES CEREVISIAE;

EID: 77956967810     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.413     Document Type: Article

References (36)

1. Subramani K, Hosseinkhani H, Khraisat A, Hosseinkhani M, Pathak Y. Targeting nanoparticles as drug delivery systems for cancer treatment. Curr Nanosci. 2009;5:134-140.
2. Hosseinkhani H, Hosseinkhani M, Gabrielson NP, Pack DW, Khademhosseini A, Kobayashi H. DNA nanoparticles encapsulated in 3D tissue-engineered scaffolds enhance osteogenic differentiation of mesenchymal stem cells. J Biomed Mater Res A. 2008;85:47-60.
3. Hosseinkhani H. DNA nanoparticles for gene delivery to cells and tissue. Int J Nanotechnol. 2006;3:416-461.
4. Hosseinkhani H, Tabata Y. Self assembly of DNA nanoparticles with polycations for the delivery of genetic materials into cells. J Nanosci Nanotechnol. 2006;6:2320-2328.
5. Hosseinkhani H, Hosseinkhani M, Khademhosseini A, Kobayashi H. Bone regeneration through controlled release of bone morphogenetic protein-2 from 3-D tissue engineered nano-scaffold. J Control Release. 2007;117:380-386.
6. Hosseinkhani H, Hosseinkhani M, Tian F, Kobayashi H, Tabata Y. Osteogenic differentiation of mesenchymal stem cells in selfassembled peptide-amphiphile nanofibers. Biomaterials. 2006;27: 4079-4086.
7. MacIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks LM, Healy MJ. Calcitonin for prevention of postmenopausal bone loss. Lancet. 1988;8591:900-902.
8. Kraenzlin ME, Seibel MJ, Trechsel U, Boerlin V, Azria M, Kraenzlin CA, Haas HG. The effect of intranasal salmon calcitonin on postmenopausal bone turnover as assessed by biochemical markers: evidence of maximal effect after 8 weeks of continuous treatment. Calcif Tissue Int. 1996;58:216-220.
9. Chesnut CH III, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int. 2008;19:479-491.
10. Tankó LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res. 2004;19:1531-1538.
11. Schneyer CR. Calcitonin and the treatment of osteoporosis. Md Med J. 1991;40:469-473.
12. Karsdal MA, Henriksen K, Arnold M, Christiansen C. Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs. 2008;22:137-144.
13. Sakuma S, Suzuki N, Kikuchi H, Hiwatari K, Arikawa K, Kishida A, Akashi M. Oral peptide delivery using nanoparticles composed of novel graft copolymers having hydrophobic backbone and hydrophilic branches. Int J Pharm. 1997;149:93-106.
14. Yamabe K, Kato Y, Onishi H, Machida Y. Potentiality of double liposomes containing salmon calcitonin as an oral dosage form. J Control Release. 2003;89:429-436.
15. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. pHsensitive microsphere delivery increases oral bioavailability of calcitonin. J Control Release. 2004;98:1-9.
16. Garcia-Fuentes M, Torres D, Alonso MJ. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm. 2005;296:122-132.
17. Smoum R, Rubinstein A, Srebnik M. Chitosan-pentaglycine- phenylboronic acid conjugate: a potential colon-specific platform for calcitonin. Bioconjug Chem. 2006;17:1000-1007.
18. Blanquet S, Marol-Bonnin S, Beyssac E, Pompon D, Renaud M, Alric M. The biodrug concept: an innovative approach to therapy. Trends Biotechnol. 2001;19:393-400.
19. Blanquet S, Antonelli R, Laforet L, Denis S, Marol-Bonnin S, Alric M. Living recombinant Saccharomyces cerevisiae secreting proteins or peptides as a new drug delivery system in the gut. J Biotechnol. 2004;110:37-49.
20. Kondo A, Ueda M. Yeast cell-surface display-applications of molecular display. Appl Microbiol Biotechnol. 2004;64:28-40.
21. Horton RM, Ho SN, Pullen JK, Hunt HD, Cai Z, Pease LR. Gene splicing by overlap extension. Methods Enzymol. 1993; 217:270-279.
22. Gietz RD, Woods RA. Transformation of yeast by lithium acetate/ single-stranded carrier DNA/polyethylene glycol method. Guide Yeast Genet Mol Cell Biol. 2002;350:87-96.
23. Hall JF, Webb TJB. Factors affecting the survival of lyophilized brewery strains. J Inst Brew. 1975;81:471-475.
24. Berny JF, Hennebert GL. Viability and stability of yeast cells and filamentous fungus spores during freeze drying: effects of protectants and cooling rates. Mycologia. 1991;83:805-815.
25. Cerrutti P, Segovia de Huergo M, Galvagno M, Schebor C, del Pilar Buera M. Commercial baker's yeast stability as affected by intracellular content of trehalose, dehydration procedure and the physical properties of external matrices. Appl Microbiol Biotechnol. 2000;54:575-580.
26. Lakkakorpi P, Tuukkanen J, Hentunen T, Järvelin K, Väänänen K. Organization of osteoclast microfilaments during the attachment to bone surface in vitro. J Bone Miner Res. 1989;4:817-825.
27. Hirayama T, Sabokbar A, Itonaga I, Watt-Smith S, Athanasou NA. Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease. J Pathol. 2001;195: 624-630.
28. Karsdal MA, Byrjalsen I, Azria M, Arnold M, Choi L, Riis BJ, Christiansen C. Influence of food intake on the bioavailability and efficacy of oral calcitonin. Br J Clin Pharmacol. 2009;67: 413-420.
29. Sharp PM, Cowe E, Higgins DG, Shields DC, Wolfe KH, Wright F. Codon usage patterns in Escherichia coli,Bacillus subtilis,Saccharomyces cerevisiae,Schizosaccharomyces pombe,- Drosophila melanogaster and Homo sapiens; a review of the considerable within-species diversity. Nucleic Acids Res. 1988;16:8207-8211.
30. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotech. 1997;15:553-557.
31. Lee VHL, Yamaoto A. Penetration and enzymatic barriers to peptide and protein absorption. Adv Drug Deliv Rev. 1990;4:171-207.
32. Zhu K, Chi Z, Li J, Zhang F, Li M, Yasoda HN, Wu L. The surface display of haemolysin from Vibrio harveyi on yeast cells and their potential applications as live vaccine in marine fish. Vaccine. 2006;24:6046-6052.
33. Yuan X, Zheng X, Lu D, Rubin DC, Pung CY, Sadler JE. Structure of murine enterokinase (enteropeptidase) and expression in small intestine during development. Am J Physiol. 1998;274:G342-G349.
34. Hosseinkhani H, Hosseinkhani M, Khademhosseini A, Kobayashi H, Tabata Y. Enhanced angiogenesis through controlled release of basic fibroblast growth factor from peptide amphiphile for tissue regeneration. Biomaterials. 2006;27:5836-5844.
35. Hong B, Wu B, Li Y. Production of C-terminal amidated recombinant salmon calcitonin in Streptomyces lividans. Appl Biochem Biotechnol. 2003;110:113-123.
36. Farland LM, Bernasconi P. Saccharomyces boulardii: a review of an innovative biotherapeutic agent. Microbiol Ecol Health Dis. 1993;6:157-171.